105 related articles for article (PubMed ID: 19001608)
1. Re: Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.
Giorgi Rossi P; Zappa M
J Natl Cancer Inst; 2008 Nov; 100(22):1654; author reply 1654-5. PubMed ID: 19001608
[No Abstract] [Full Text] [Related]
2. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.
Goldhaber-Fiebert JD; Stout NK; Salomon JA; Kuntz KM; Goldie SJ
J Natl Cancer Inst; 2008 Mar; 100(5):308-20. PubMed ID: 18314477
[TBL] [Abstract][Full Text] [Related]
3. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India.
Diaz M; Kim JJ; Albero G; de Sanjosé S; Clifford G; Bosch FX; Goldie SJ
Br J Cancer; 2008 Jul; 99(2):230-8. PubMed ID: 18612311
[TBL] [Abstract][Full Text] [Related]
4. Screening for cervical cancer in the era of the HPV vaccine--the urgent need for both new screening guidelines and new biomarkers.
Kiviat NB; Hawes SE; Feng Q
J Natl Cancer Inst; 2008 Mar; 100(5):290-1. PubMed ID: 18314471
[No Abstract] [Full Text] [Related]
5. [Implementation of HPV vaccination in Germany].
Schreckenberger C; Kaufmann AM; Schneider A
Dtsch Med Wochenschr; 2007 Oct; 132(42):2221-4. PubMed ID: 17926251
[No Abstract] [Full Text] [Related]
6. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination.
Chen MK; Hung HF; Duffy S; Yen AM; Chen HH
J Eval Clin Pract; 2011 Dec; 17(6):1050-8. PubMed ID: 21679279
[TBL] [Abstract][Full Text] [Related]
8. The road to cervical cancer elimination in Malaysia: Evaluation of the impact and cost-effectiveness of human papillomavirus screening with self-collection and digital registry support.
Keane A; Ng CW; Simms KT; Nguyen D; Woo YL; Saville M; Canfell K
Int J Cancer; 2021 Dec; 149(12):1997-2009. PubMed ID: 34363620
[TBL] [Abstract][Full Text] [Related]
9. [Vaccination perspective against human papillomavirus and consequences for the screening of uterine cervical neoplasm].
Delvenne P
Bull Mem Acad R Med Belg; 2007; 162(10-12):483-8; discussion 489-90. PubMed ID: 18557390
[TBL] [Abstract][Full Text] [Related]
10. Screening: Testing times.
Humphries C
Nature; 2012 Aug; 488(7413):S8-9. PubMed ID: 22932440
[No Abstract] [Full Text] [Related]
11. Primary and secondary prevention of cervical cancer--opportunities and challenges.
Markowitz LE; Unger ER; Saraiya M
J Natl Cancer Inst; 2009 Apr; 101(7):439-40. PubMed ID: 19318638
[No Abstract] [Full Text] [Related]
12. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing.
Schiffman M
Cancer; 2007 Jun; 111(3):145-53. PubMed ID: 17487850
[TBL] [Abstract][Full Text] [Related]
13. HPV and cervical cancer: screening or vaccination?
Bosch FX; Castellsagué X; de Sanjosé S
Br J Cancer; 2008 Jan; 98(1):15-21. PubMed ID: 18182975
[TBL] [Abstract][Full Text] [Related]
14. Choosing the optimal HPV vaccine: The health impact and economic value of the nonavalent and bivalent HPV vaccines in 48 Gavi-eligible countries.
Burger EA; Portnoy A; Campos NG; Sy S; Regan C; Kim JJ
Int J Cancer; 2021 Feb; 148(4):932-940. PubMed ID: 32706907
[TBL] [Abstract][Full Text] [Related]
15. Impact and Cost-Effectiveness of Human Papillomavirus Vaccination Campaigns.
Portnoy A; Campos NG; Sy S; Burger EA; Cohen J; Regan C; Kim JJ
Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):22-30. PubMed ID: 31666282
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of human papilloma virus vaccination in Iceland.
Oddsson K; Johannsson J; Asgeirsdottir TL; Gudnason T
Acta Obstet Gynecol Scand; 2009; 88(12):1411-6. PubMed ID: 19900074
[TBL] [Abstract][Full Text] [Related]
17. [Cytology and DNA HPV-testing in the era of HPV-vaccine].
Spaczyński M; Malkowska-Walczak B; Nowak-Markwitz E
Ginekol Pol; 2007 Sep; 78(9):696-700. PubMed ID: 18159823
[TBL] [Abstract][Full Text] [Related]
18. A public health approach to cervical cancer control: considerations of screening and vaccination strategies.
Goldie S
Int J Gynaecol Obstet; 2006 Nov; 94 Suppl 1():S95-105. PubMed ID: 17276172
[TBL] [Abstract][Full Text] [Related]
19. Summaries for patients. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States.
Ann Intern Med; 2009 Oct; 151(8):I36. PubMed ID: 19841439
[No Abstract] [Full Text] [Related]
20. Cost-effectiveness of HPV 16, 18 vaccination in Brazil.
Goldie SJ; Kim JJ; Kobus K; Goldhaber-Fiebert JD; Salomon J; O'shea MK; Xavier Bosch F; de Sanjosé S; Franco EL
Vaccine; 2007 Aug; 25(33):6257-70. PubMed ID: 17606315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
